Mononuclear cell response to lipopolysaccharide in patients with rheumatoid arthritis: Relationship with tristetraprolin expression

Journal of Rheumatology

Volumn 32, Issue 6, 2005, Pages 998-1005

  Fabris, Martina ^a   Tolusso, Barbara ^a   Di Poi, Emma ^a   Tomietto, Paola ^a   Sacco, Stefania ^a   Gremese, Elisa ^a   Ferraccioli, Gianfranco ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

Author keywords

Lipopolysaccharide; Mononuclear cells; Rheumatoid arthritis; Tristetraprolin; Tumor necrosis factor

Indexed keywords

DISEASE MODIFYING ANTIRHEUMATIC DRUG; DNA BINDING PROTEIN; LIPOPOLYSACCHARIDE; MESSENGER RNA; PROTEIN TRISTETRAPROLIN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD DONOR; CELL ACTIVITY; CELL STIMULATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE COURSE; DISEASE PREDISPOSITION; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; MONONUCLEAR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PREVALENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION; RHEUMATOID ARTHRITIS;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; CELLS, CULTURED; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION; HUMANS; IMMEDIATE-EARLY PROTEINS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; PROGNOSIS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; RNA, MESSENGER; TIME FACTORS; TRISTETRAPROLIN; TUMOR NECROSIS FACTOR-ALPHA; ZINC FINGERS;

EID: 20444474941     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Feldmann M, Brennan F, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996;14:397-440.
2. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin-1 and tumour necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
3. Elliott MJ, Maini RN, Feldmann M, et al. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor a. Arthritis Rheum 1995;36:1681-90.
4. Maini R, St. Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomized phase III trial. Attract Study Group. Lancet 1999;354:1932-9.
5. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumour necrosis factor receptor (p75)-Fc fusion protein. N Engl J Med 1997;337:141-7.
6. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumour necrosis factor receptor Fc-fusion protein, in patients with rheumatoid arthritis receiving MTX. N Engl J Med 1999;340:253-9.
7. Lipsky PE, van der Heijde DM, St. Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-tumour Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med 2000;343:1594-602.
8. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum 1998;41:2196-204.
9. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumour necrosis factor α monoclonal antibody treatment in patients with rheumatoid arthritis. Arthritis Rheum 1996;41:1258-65.
10. Paleolog EM, Young S, Stark AC, McCloskey RV, Feldmann M, Maini RN. Modulation of angiogenic vascular endothelial growth factor α and interleukin-1 in rheumatoid arthritis. Arthritis Rheum 1998;41:1258-65.
11. Burmester GR, Stuhlmuller B, Keyszer G, Kinne RW. Mononuclear phagocytes and rheumatoid synovitis: mastermind or work-horse? Arthritis Rheum 1997;40:5-18.
12. Iwahashi M, Yamamura M, Aita T, et al. Expression of Toll-like receptor 2 on CD16+ blood monocytes and synovial tissue macrophages in rheumatoid arthritis. Arthritis Rheum 2004;50:1457-67.
13. Ohashi K, Burkart V, Flohe S, Kolb H. Cutting edge: heat shock protein 60 is a putative endogenous ligand of the toll-like receptor 4 complex. J Immunol 2000;164:558-61.
14. Guha M, Mackman N. LPS induction of gene expression in human monocytes. Cell Signal 2001;13:85-91.
15. Erridge C, Stewart J, Poxton IR. Monocytes heterozygous for the Asp299Gly and Thr399Ile mutations in the Toll-like receptor 4 gene show no deficit in lipopolysaccharide signalling. J Exp Med 2003;197:1787-91.
16. Anderson P, Phillips K, Stoecklin G, Kedersha N. Post-transcriptional regulation of proinflammatory proteins. J Leukoc Biol 2004;76:42-7.
17. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of RA. Arthritis Rheum 1998;31:315-24.
18. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 1996;39:34-40.
19. Tolusso B, Fabris M, Di Poi E, Assaloni R, Tomietto P, Ferraccioli GF. Response of mononuclear cells to lipopolysaccharide and CpG oligonucleotide stimulation: possible additive effect in rheumatoid inflammation. Ann Rheum Dis 2002;62:284-5,
20. Smeets TJM, Kraan MC, Galjaard S, Youssef PP, Smith MD, Tak PP. Analysis of the cell infiltrate and expression of matrix metalloproteinases and granzyme B in paired synovial biopsy specimens from the cartilage-pannus junction in patients with RA. Ann Rheum Dis 2001;60:561-5.
21. Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis factor alpha production by tristetraprolin. Science 1998;28:1001-5.
22. Suzuki T, Hashimoto S, Toyoda N, et al. Comprehensive gene expression profile of LPS-stimulated human monocytes by SAGE. Blood 2000;96:2584-91.
23. Smeets TJM, Dolhain RJEM, Breedveld FC, Tak PP. Analysis of the cellular infiltrates and expression of cytokines in synovial tissue from patients with rheumatoid arthritis and reactive arthritis. J Pathol 1998;186:75-81.
24. Katrib A, Tak PP, Bertouch JV, et al. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology Oxford 2001;40:988-94.
25. Baeten D, Demetter P, Cuvelier C, et al. Comparative study of the synovial histology in rheumatoid arthritis, spondyloarthropathy, and osteoarthritis: influence of disease duration and activity. Ann Rheum Dis 2000;59:945-53.
26. Catrina AI, Ulfgren AK, Lindblad S, Grondal L, Klareskog L. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. Ann Rheum Dis 2002;61:934-6.
27. Gerli R, Bistoni O, Russano A, et al. In vivo activated T cells in rheumatoid synovitis. Analysis of Th1- and Th2-type cytokine production at clonal level in different stages of disease. Clin Exp Immunol 2002;129:549-55.
28. Tak PP, Breedveld FC. Current perspectives on synovitis. Arthritis Res 1999;1:11-6.
29. Liote F, Boval-Boizard B, Weill D, Kuntz D, Wantier JL. Blood monocyte activation in rheumatoid arthritis: increased monocyte adhesiveness, integrin expression and cytokine release. Clin Exp Immunol 1996;106:13-9.
30. Swaak AJG, van den Brink HG, Aarden LA. Cytokine production in whole blood cell cultures of patients with rheumatoid arthritis. Ann Rheum Dis 1997;56:693-5.
31. Rodenburg RJ, van den Hoogen FH, van de Putte LBA, van Venroij WJ. Peripheral blood monocytes of rheumatoid arthritis patients do not express elevated TNF-α, IL-1β and IL-8 mRNA levels. A comparison of monocyte isolation procedures. J Immunol Methods 1998;221:169-75.
32. Verbruggen A, De Clerk LS, Bridts CH, Van Offel JF, Stevens WJ. Flow cytometrical determination of interleukin 1 beta, interleukin 6 and tumor necrosis factor-α in monocytes of rheumatoid arthritis patients: relation with parameters of osteoporosis. Cytokine 1999;11:869-74.
33. Leirisalo-Repo M, Paimela L, Jaatela M, Koskimies S, Repo H. Production of TNF by monocytes of patients with early RA is increased. Scand J Rheumatol 1995;24:366-71.
34. Hart PH, Ahern MJ, Jones KL, Smith MD, Finlay-Jones JJ. Synovial fluid macrophages and blood monocytes differ in their response to IL-4. J Immunol 1993;151:3370-80.
35. Triggiani M, Granata F, Oriente A, et al. Secretory phospholipases A2 induce cytokine release from blood and synovial fluid monocytes. Eur J Immunol 2002;32:67-76.
36. Cope AP Exploring the reciprocal relationship between immunity and inflammation in chronic inflammatory arthritis. Rheumatology Oxford 2003;42:716-31.
37. Anderson JJ, Wells G, Verhoeven AC, Felson DT. Factors predicting response to treatment in rheumatoid arthritis: the importance of disease duration. Arthritis Rheum 2000;43:22-9.
38. Tamandl D, Bahrami M, Wessner B, et al. Modulation of Toll-like receptor 4 expression on human monocytes by tumor necrosis factor and interleukin 6: tumor necrosis factor evokes lipopolysaccharide hyporesponsiveness, whereas interleukin 6 enhances lipopolysaccharide activity. Shock 2003;20:224-9.
39. Raabe T, Bukrinsky M, Currie RA. Relative contribution of transcription and translation to the induction of tumor necrosis factor α by lipopolysaccharide. J Biol Chem 1998;273:974-80.
40. Swantek JL, Cobb MH, Geppert TD. Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK) is required for LPS stimulation of TNF-α translation: glucocorticoids inhibit TNF-α translation by blocking JNK/SAPK. Mol Cell Biol 1997;17:6274-82.
41. Rutault K, Hazzalin CA, Mahadevan LC. Combinations of ERK and p38 MAPK inhibitors ablate TNF-α mRNA induction. Evidence for selective destabilization of TNF-α transcripts. J Biol Chem 2001;276:6666-74.
42. Carballo E, Gilkeson GS, Blackshear PJ. Bone marrow transplantation reproduces the tristetraprolin-deficiency syndrome in recombination activating gene-2(-/-)mice: evidence that monocyte/macrophage progenitors may be responsible for TNF-α overproduction. J Clin Invest 1997;100:986-95.
43. Brooks SA, Connolly JE, Diegel RJ, Fava RA, Rigby WFC. Analysis of the function, expression and subcellular distribution of human tristetraprolin. Arthritis Rheum 2002;46:1362-70.
44. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. Arthritis Rheum 2003;48:1849-52.
45. Krakt M, Saklatvala J. Transcriptional and post-transcriptional control of gene expression in inflammation. Cytokine 2002;20:91-106.